directors
Professor Bryan R.G. Williams, PhD
Non-Executive Chairman
Professor Williams was appointed Chairman of the Board of Directors in November 2006. He has been one of the Company's directors since March 2006. Professor Williams has over 30 years of experience in basic and pre-clinical cancer research. Since January 2006, he has been the director of the Monash Institute of Medical Research in Melbourne, Australia. From 1991 to 2005, Professor Williams was Chairman of the Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. From 1993 to 2005, he was Professor, Department of Genetics at Case Western Reserve University, Cleveland, Ohio. From 1998 to 2005, he was an Adjunct Professor in the Departments of Chemistry at Cleveland State University and Kent State University, also both in Ohio. Professor Williams holds a BSc. (Hons) (Microbiology) and Ph.D. (Microbiology) from the University of Otago, New Zealand. He is an Honorary Fellow of the Royal Society of New Zealand.
Charles V. Baltic III, JD
Non-Executive Director
Mr. Baltic was appointed as a director of Marshall Edwards in October 2011. He has more than 19 years of experience working with life science and healthcare companies in a significant variety of transactional contexts. During that time he has been involved in raising more than $7 billion in life science financings. Mr. Baltic is currently Managing Director and Co-Head of Healthcare at Needham & Company. Prior to joining Needham in 2009, he was Managing Director and head of the biotechnology practice at CRT Capital Group. Previously, he served as Managing Director in Healthcare Investment Banking at Wachovia Securities, where he founded and headed its biotechnology practice. Prior to that, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director in life sciences. Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with Dewey Ballantine, representing numerous healthcare and securities clients. He holds BA and JD degrees from Georgetown University and an MBA degree in finance from the Wharton School of the University of Pennsylvania. He is also a founding Trustee and Current Chair of the Programs Committee of the non-profit Hope Funds for Cancer Research. Mr. Baltic is a former Director of Med-Vantage Inc., which was acquired by IMS Health in 2011.
Leah R. Cann, MBA
Non-Executive Director
Ms. Cann has been a director of Marshall Edwards since March 2009. She is an independent research analyst in Newport, Rhode Island. Ms. Cann began her career as a research scientist with Memtec Corporation and moved to Wall Street in 1992, where she was a research analyst with CIBC Oppenheimer for nearly nine years. She was a heath care analyst for the Boston-based asset manager, Cadence Capital, and later the senior biotechnology analyst for Wachovia Securities. Twice recognized as an All-Star analyst by the Wall Street Journal, Ms. Cann is the founder of Leah Rush Cann Research and Consulting, LLC, a cancer consulting organization. Ms. Cann has been a trustee and member of several committees of International House in New York City for more than 10 years. She is a trustee and the chairman of the Executive Committee of the Hope Funds for Cancer Research, which she helped found in 2006. Ms. Cann received a BA in Art History and Chemistry and an MBA from Stetson University. She was a post-baccalaureate at the College of William and Mary and a post-graduate at Columbia University.
Daniel P. Gold, PhD
President & Chief Executive Officer
Dr. Gold was appointed President, Chief Executive Officer and a director of Marshall Edwards in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a B.A. in Biology from the University of California Los Angeles.
William D. Rueckert
Non-Executive Director
Mr. Rueckert was elected as a director of Marshall Edwards in April 2011. Mr. Rueckert previously served as a director of the Company from March 2007 until March 2009, when he was appointed as a director of Novogen Limited. He was elected Chairman of the Novogen board of directors in October 2010. Mr. Rueckert is the Managing Member of Oyster Management Group LLC, an investment fund specializing in community banks. Previously, he was President and Director of Rosow & Company, a private investment firm based in Connecticut, President and Director of Eastern Capital Development, LLC, Treasurer of Moore & Munger, Inc., a company with interests in the petroleum and resort development industries, and President of United States Oil Company, a publicly traded oil exploration business. In addition to Marshall Edwards and Novogen, he also serves as a member of the board of directors of Chelsea Therapeutics International, Ltd., a publicly traded biopharmaceutical company. Among his many civic associations, Mr. Rueckert is Director and President of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City, and Chairman of the Board of the Trustees of Teachers College, Columbia University.
Christine A. White, MD
Non-Executive Director
Dr. White was appointed as a director of Marshall Edwards in August 2010. She was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played an integral role in the clinical development, regulatory affairs and commercialization of oncology drugs Rituxan® and Zevalin®. Previously, she served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego, and in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, most recently as Chairman. Dr. White currently serves as a member of the board of directors of Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, and Genoptix, a specialized laboratory services provider. She also served as a director of Pharmacyclics, a biopharmaceutical company, and Monogram Biosciences, a life sciences company, until its acquisition by LabCorp in August 2009. Dr. White earned her B.A. in Biology and her M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology.